Open AccessEstimation and comparison of salivary secretory leukocyte protease inhibitor in human immunodeficiency virus patients and healthy individuals
Author(s) -
Kumar Pushpanshu,
Ramhari Sathawane,
Rachna Kaushik
Publication year - 2014
Publication title -
indian journal of palliative care/indian journal of palliative care
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.395
H-Index - 26
eISSN - 1998-3735
pISSN - 0973-1075
DOI - 10.4103/0973-1075.125551
Subject(s) - slpi , saliva , protease inhibitor (pharmacology) , medicine , immunology , virus , human immunodeficiency virus (hiv) , protease , disease , virology , enzyme , biology , viral load , antiretroviral therapy , inflammation , biochemistry
Transmission of human immunodeficiency virus (HIV) in the oral cavity is a rare event, despite detectable virus in saliva and oropharyngeal tissues of infected persons, unlike other mucosal sites. Secretory leukocyte protease inhibitor (SLPI) has been suggested as the main soluble factor responsible for the HIV inhibitory effect of saliva. The study was designed to estimate and compare the salivary SLPI levels in HIV patients and healthy controls. Furthermore, the relationship between salivary SLPI levels and disease severity was also investigated.